These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 20012337)

  • 1. A phase II study of everolimus in combination with imatinib for previously treated advanced renal carcinoma.
    Ryan CW; Vuky J; Chan JS; Chen Z; Beer TM; Nauman D
    Invest New Drugs; 2011 Apr; 29(2):374-9. PubMed ID: 20012337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors.
    Schöffski P; Reichardt P; Blay JY; Dumez H; Morgan JA; Ray-Coquard I; Hollaender N; Jappe A; Demetri GD
    Ann Oncol; 2010 Oct; 21(10):1990-1998. PubMed ID: 20507881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.
    Bitting RL; Healy P; Creel PA; Turnbull J; Morris K; Wood SY; Hurwitz HI; Starr MD; Nixon AB; Armstrong AJ; George DJ
    Clin Genitourin Cancer; 2014 Aug; 12(4):241-50. PubMed ID: 24685058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of imatinib (Gleevec) in patients with metastatic renal cell carcinoma.
    Vuky J; Isacson C; Fotoohi M; dela Cruz J; Otero H; Picozzi V; Malpass T; Aboulafia D; Jacobs A
    Invest New Drugs; 2006 Jan; 24(1):85-8. PubMed ID: 16380835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of imatinib in patients with advanced anaplastic thyroid cancer.
    Ha HT; Lee JS; Urba S; Koenig RJ; Sisson J; Giordano T; Worden FP
    Thyroid; 2010 Sep; 20(9):975-80. PubMed ID: 20718683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase II study of pulse dose imatinib mesylate and weekly paclitaxel in patients aged 70 and over with advanced non-small cell lung cancer.
    Bauman JE; Eaton KD; Wallace SG; Carr LL; Lee SJ; Jones DV; Arias-Pulido H; Cerilli LA; Martins RG
    BMC Cancer; 2012 Oct; 12():449. PubMed ID: 23033932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma.
    Hainsworth JD; Spigel DR; Burris HA; Waterhouse D; Clark BL; Whorf R
    J Clin Oncol; 2010 May; 28(13):2131-6. PubMed ID: 20368560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy of imatinib mesylate and interferon-alpha demonstrates minimal activity and significant toxicity in metastatic renal cell carcinoma: results of a single- institution phase II trial.
    Polite BN; Desai AA; Manchen B; Stadler WM
    Clin Genitourin Cancer; 2006 Mar; 4(4):275-80. PubMed ID: 16729911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Experience with everolimus therapy for patients with metastatic renal cancer in Hungary].
    Maráz A; Bodoky G; Dank M; Géczi L; Kahán Z; Mangel L; Révész J; Szűcs M
    Magy Onkol; 2014 Mar; 58(1):4-9. PubMed ID: 24712001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus.
    Huh WK; Sill MW; Darcy KM; Elias KM; Hoffman JS; Boggess JF; Alvarez RD; Long HJ; O'Malley DM; Birrer MJ
    Gynecol Oncol; 2010 May; 117(2):248-54. PubMed ID: 20189232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Community Oncology Setting.
    Vogelzang NJ; Hackshaw MD; Hutson TE; Bhowmik D; Yap M; Rembert D; Jonasch E
    Clin Genitourin Cancer; 2015 Jun; 13(3):210-7. PubMed ID: 25498215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial.
    Hainsworth JD; Spigel DR; Sosman JA; Burris HA; Farley C; Cucullu H; Yost K; Hart LL; Sylvester L; Waterhouse DM; Greco FA
    Clin Genitourin Cancer; 2007 Dec; 5(7):427-32. PubMed ID: 18272024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.
    Choueiri TK; Escudier B; Powles T; Tannir NM; Mainwaring PN; Rini BI; Hammers HJ; Donskov F; Roth BJ; Peltola K; Lee JL; Heng DYC; Schmidinger M; Agarwal N; Sternberg CN; McDermott DF; Aftab DT; Hessel C; Scheffold C; Schwab G; Hutson TE; Pal S; Motzer RJ;
    Lancet Oncol; 2016 Jul; 17(7):917-927. PubMed ID: 27279544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of everolimus in patients with advanced renal cell carcinoma refractory or intolerant to VEGFR-TKIs and safety compared with prior VEGFR-TKI treatment.
    Kato R; Obara W; Matsuura T; Kato Y; Iwasaki K; Fujioka T
    Jpn J Clin Oncol; 2014 May; 44(5):479-85. PubMed ID: 24688083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study.
    Hotte SJ; Winquist EW; Lamont E; MacKenzie M; Vokes E; Chen EX; Brown S; Pond GR; Murgo A; Siu LL
    J Clin Oncol; 2005 Jan; 23(3):585-90. PubMed ID: 15659505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma.
    Tsao AS; Liu S; Fujimoto J; Wistuba II; Lee JJ; Marom EM; Charnsangavej C; Fossella FV; Tran HT; Blumenschein GR; Papadimitrakopoulou V; Kies MS; Hong WK; Stewart DJ
    J Thorac Oncol; 2011 Dec; 6(12):2104-11. PubMed ID: 21892101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive, extensive-stage small-cell lung cancer.
    Schneider BJ; Kalemkerian GP; Ramnath N; Kraut MJ; Wozniak AJ; Worden FP; Ruckdeschel JC; Zhang X; Chen W; Gadgeel SM
    Clin Lung Cancer; 2010 Jul; 11(4):223-7. PubMed ID: 20630823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma.
    Frank-Raue K; Fabel M; Delorme S; Haberkorn U; Raue F
    Eur J Endocrinol; 2007 Aug; 157(2):215-20. PubMed ID: 17656601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter phase II study of everolimus in patients with progressive unresectable adenoid cystic carcinoma.
    Kim DW; Oh DY; Shin SH; Kang JH; Cho BC; Chung JS; Kim H; Park KU; Kwon JH; Han JY; Kim MJ; Bang YJ
    BMC Cancer; 2014 Nov; 14():795. PubMed ID: 25362970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
    Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
    Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.